Double strand ID	siRNA (mg/kg)	Complement activity (n=4, average)				
		-1 Day	7 Day	13 Day	20 Day	27 Day
PBS	-	100%	113%	124%	111%	124%
siRNA-008-34	0.3	100%	16%	38%	12%	27%
siRNA-008-34	1	100%	6%	26%	7%	23%
siRNA-008-34	3	100%	2%	10%	2%	10%

Double strand ID	siRNA (mg/kg)	Complement activity (n=4, average)			
		34 Day	41 Day	48 Day	55 Day
PBS	-	145%	120%	138%	122%
siRNA-008-34	0.3	19%	32%	19%	37%
siRNA-008-34	1	11%	17%	12%	22%
siRNA-008-34	3	7%	10%	8%	17%

[0131] [Example 11: Pharmacological test (hemolysis-suppressing effect with administration once every three weeks)]

(Preparation of siRNA-LNPs)

Lipid nanoparticles (LNPs) encapsulating siRNA therein were prepared in the same manner as in Example 8.

[0132] (In-vivo evaluation)

LNPs encapsulating PBS or siRNA listed in Table 21 of Example 8 therein were intravenously administered to a BALB/c mouse (male, 7 weeks old, n = 4 per group) from the tail vein at a dose of 0.3, 1 and 3 mg/kg siRNA once every three weeks (Q3w). The blood was sampled under anesthesia on the day before the administration (-1 Day in Table 26), and 7 days, 13 days, 20 days, 27 days, 34 days, 41 days, 48 days and 55 days after the administration

Double strand ID	siRNA (mg/kg)	Complement activity (n=4, average)				
		-1 Day	7 Day	13 Day	20 Day	27 Day
PBS	-	100%	102%	102%	108%	103%
siRNA-008-34	0.3	100%	22%	45%	75%	22%
siRNA-008-34	1	100%	3%	16%	33%	6%
siRNA-008-34	3	100%	5%	13%	29%	6%

Double strand ID	siRNA (mg/kg)	Complement activity (n=4, average)			
		34 Day	41 Day	48 Day	55 Day
PBS	-	120%	79%	109%	117%
siRNA-008-34	0.3	52%	58%	24%	40%
siRNA-008-34	1	17%	33%	8%	18%
siRNA-008-34	3	16%	23%	6%	25%

SEQUENCE LISTING

WHAT IS CLAIMED IS:

1. A double-stranded ribonucleic acid comprising:

a combination of a sense strand and an antisense strand,

wherein the combination of the sense strand and the antisense strand are selected from the group consisting of combinations:

SEQ ID NO: 159 and SEQ ID NO: 160; SEQ ID NO: 141 and SEQ ID NO: 142; SEQ ID NO: 143 and SEQ ID NO: 144; SEQ ID NO: 145 and SEQ ID NO: 146; SEQ ID NO: 147 and SEQ ID NO: 148; and SEQ ID NO: 153 and SEQ ID NO: 154.

2. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 159; and an antisense strand of SEQ ID NO: 160.

3. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 141; and an antisense strand of SEQ ID NO: 142.

4. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 143; and an antisense strand of SEQ ID NO: 144.

5. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 145; and an antisense strand of SEQ ID NO: 146.

6. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 147; and an antisense strand of SEQ ID NO: 148.

7. A double-stranded ribonucleic acid comprising a sense strand of SEQ ID NO: 153; and an antisense strand of SEQ ID NO: 154.

8. A pharmaceutical composition comprising:

the double-stranded ribonucleic acid according to any one of claims 1 to 7.

9. The pharmaceutical composition according to claim 8, for treating paroxysmal nocturnal hemoglobinuria.

10. The pharmaceutical composition according to claim 8, for treating atypical hemolytic uremic syndrome.

11. A lipid complex encapsulating the double-stranded ribonucleic acid according to any one of claims 1 to 7.

12. The lipid complex according to claim 11, comprising:

a cationic lipid; and

at least one lipid selected from the group consisting of neutral lipid, polyethylene glycol-modified lipid, and sterol.

13. The lipid complex according to claim 12, wherein the cationic lipid is 2-{9-oxo-9-[(3-pentyloctyl)oxy]nonyl}dodecyl 1-methylpiperidine-4-carboxylate.

14. A pharmaceutical composition comprising:

the lipid complex according to any one of claims 11 to 13.

15. The pharmaceutical composition according to claim 14, for treating paroxysmal nocturnal hemoglobinuria.

16. The pharmaceutical composition according to claim 14, for treating atypical hemolytic uremic syndrome.

17. The double-stranded ribonucleic acid according to any one of claims

1 to 7, for use in treating paroxysmal nocturnal hemoglobinuria.

18. The double-stranded ribonucleic acid according to any one of claims 1 to 7, for use in treating atypical hemolytic uremic syndrome.

19. The lipid complex according to any one of claims 11 to 13, for use in treating paroxysmal nocturnal hemoglobinuria.

20. The lipid complex according to any one of claims 11 to 13, for use in treating atypical hemolytic uremic syndrome.

21. Use of the double-stranded ribonucleic acid according to any one of claims 1 to 7, in the manufacture of a pharmaceutical composition for treating paroxysmal nocturnal hemoglobinuria.

22. Use of the double-stranded ribonucleic acid according to any one of claims 1 to 7, in the manufacture of a pharmaceutical composition for treating atypical hemolytic uremic syndrome.

23. Use of the lipid complex according to any one of claims 11 to 13, in the manufacture of a pharmaceutical composition for treating paroxysmal nocturnal hemoglobinuria.

24. Use of the lipid complex according to any one of claims 11 to 13, in the manufacture of a pharmaceutical composition for treating atypical hemolytic uremic syndrome.